Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. STTK
STTK logo

STTK Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Shattuck Labs Inc (STTK) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.250
1 Day change
-2.80%
52 Week Range
6.810
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Shattuck Labs Inc (STTK) is not a strong buy for a beginner investor with a long-term focus at this time. While there are positive catalysts in the form of upcoming Phase 1 data and bullish analyst ratings, the company's financial performance is weak, and there are no strong trading signals or recent influential trades to support immediate action. The stock's technical indicators suggest a neutral to slightly bullish trend, but the lack of significant trading trends and weak financials make it a hold rather than a buy.

Technical Analysis

The technical indicators show a slightly bullish trend with MACD above 0 and positively contracting, RSI at 72.498 in the neutral zone, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level R1 (6.633), with a pre-market price of 6.49. However, the stock trend analysis indicates a 50% chance of a negative return over the next day, week, and month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
1
Buy
9

Positive Catalysts

  • Upcoming Phase 1 data for SL-325 in Q2 2026 is expected to highlight differentiation versus competitors, and analysts see high potential for success. The pre-market price is up 2.85%, indicating some positive sentiment.

Neutral/Negative Catalysts

  • Weak financial performance in Q4 2025, with net income down -32.58% YoY and EPS down -67.57% YoY. No significant hedge fund or insider trading trends, and no recent news or congress trading data to act as a catalyst. Stock trend analysis suggests a potential decline in the short term.

Financial Performance

In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$12.59M (down -32.58% YoY), and a significant drop in EPS (-67.57% YoY). Gross margin remained at 100%, but overall financials are weak and do not support a strong buy case.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are generally bullish, with multiple firms raising price targets significantly. Needham has a $14 target with a Buy rating, and Piper Sandler has a $15 target with an Overweight rating. Citi and Wedbush have also raised targets, with upside catalysts expected in Q2 2026. However, Citi maintains a Neutral rating, indicating some caution.

Wall Street analysts forecast STTK stock price to rise
3 Analyst Rating
Wall Street analysts forecast STTK stock price to rise
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 6.430
sliders
Low
4
Averages
8.33
High
15
Current: 6.430
sliders
Low
4
Averages
8.33
High
15
Citi
Neutral
maintain
$4 -> $7
AI Analysis
2026-03-13
Reason
Citi
Price Target
$4 -> $7
AI Analysis
2026-03-13
maintain
Neutral
Reason
Citi raised the firm's price target on Shattuck Labs to $7 from $4 and keeps a Neutral rating on the shares. Citi also added an "upside 90-day catalyst watch" on Shattuck. The company is slated to report initial Phase 1 data for SL-325 in healthy volunteers in Q2, the analyst tells investors in a research note. Citi believes the data could highlight SL-325's differentiation versus competing anti-TL1A antibodies.
Wedbush
Outperform
maintain
$4 -> $8
2026-03-06
Reason
Wedbush
Price Target
$4 -> $8
2026-03-06
maintain
Outperform
Reason
Wedbush raised the firm's price target on Shattuck Labs to $8 from $4 and keeps an Outperform rating on the shares. The firm notes the company reported earnings, confirmed Crohn's disease as its lead indication, and reiterated guidance for SL-325 results in Q2 2026. Wedbush looks for low ADA rates in the healthy volunteer data as initial proof of differentiation from TL1A directed competitors in addition to other markers like receptor occupancy as mechanistic evidence supporting development.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for STTK
Unlock Now

People Also Watch